# A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

> **NCT07527169** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (estimated)

## Conditions studied

- Metastatic Olfactory Neuroblastoma

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07527169
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2030-07-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527169, "A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07527169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*